Urea Cycle Disorders Treatment Market Report 2026

The urea cycle disorders treatment market size has grown steadily in recent years. It will grow from $1.37 billion in 2025 to $1.43 billion in 2026 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to lack of awareness about ucd, limited treatment options, low patient diagnosis rates, high treatment costs, dependence on hospital-based care.

The urea cycle disorders treatment market size is expected to see steady growth in the next few years. It will grow to $1.71 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growth in gene therapy research, rising adoption of precision medicine, technological advancements in ammonia monitoring, increasing pediatric patient focus, expansion of home healthcare services. Major trends in the forecast period include personalized ucd therapy development, improved ammonia scavenger formulations, enzyme replacement therapy advancements, pediatric-focused treatment innovations, home-based and remote monitoring solutions.

The rising prevalence of chronic kidney disease (CKD) is expected to drive the growth of the urea cycle disorders treatment market in the coming years. CKD is a long-term condition marked by the gradual loss of kidney function, which impairs the body’s ability to excrete metabolic waste such as urea. Urea cycle disorder treatments help manage elevated urea levels in patients with compromised kidney function. For example, in November 2023, Kidney Care UK, a UK-based kidney patient support charity, estimated that approximately 7.2 million individuals have CKD stages 1-5, with around 3.5 million experiencing advanced stages (3-5), during which symptoms become increasingly difficult to manage. Consequently, the growing number of CKD cases is fueling the expansion of the urea cycle disorders treatment market.

Leading companies in the urea cycle disorder treatment sector are leveraging strategic partnerships to advance innovative therapies and improve disease management. Strategic partnerships involve combining resources and expertise to achieve mutual benefits. For instance, in June 2024, Orsini Specialty Pharmacy, a US-based provider of personalized medications, partnered with Zevra Therapeutics Inc., a US-based rare disease therapeutics company, to serve as the pharmacy partner for OLPRUVA (sodium phenylbutyrate) oral suspension. OLPRUVA is prescribed alongside dietary management for long-term treatment of urea cycle disorders (UCDs) in adult and pediatric patients with deficiencies in carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

In November 2023, Zevra Therapeutics Inc. acquired Acer Therapeutics Inc. for $91 million, gaining access to rare disease assets, including Edsivo, currently in Phase III trials for vascular Ehlers-Danlos syndrome, and Olpruva, FDA-approved for specific urea cycle disorders. This acquisition expands Zevra’s commercial presence and diversifies its revenue stream. Acer Therapeutics Inc. is a US-based pharmaceutical company specializing in treatments for urea cycle disorders.

Major companies operating in the urea cycle disorders treatment market are Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding, Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics Inc., Orpharma Pty Ltd., Horizon Therapeutics Plc, Synlogic, Amicus Therapeutics, Sobi, PTC Therapeutics, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Protalix BioTherapeutics, Erytech Pharma, Relief Therapeutics Holding AG, Selecta Biosciences Inc., Argenx SE, Dynacure SA, Inventiva SA.

North America was the largest region in the urea cycle disorders treatment market in 2025. The regions covered in the urea cycle disorders treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urea cycle disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the urea cycle disorders treatment market by increasing costs of imported raw materials and specialized drugs used in amino acid supplements, sodium phenylbutyrate, and glycerol phenylbutyrate production. The impact is most significant in segments like enzyme replacement therapy and injectable formulations, especially in regions such as North America and Europe that rely on global supply chains. While tariffs have raised operational costs, they have also encouraged local manufacturing and innovation in cost-effective treatment solutions, ultimately supporting the development of domestic production capabilities.

The urea cycle disorders treatment market research report is one of a series of new reports that provides urea cycle disorders treatment market statistics, including urea cycle disorders treatment industry global market size, regional shares, competitors with a urea cycle disorders treatment market share, detailed urea cycle disorders treatment market segments, market trends and opportunities, and any further data you may need to thrive in the urea cycle disorders treatment industry. This urea cycle disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urea cycle disorder treatment involves managing rare genetic conditions in which the body lacks the enzymes needed to break down ammonia, leading to toxic accumulation. The goal of treatment is to lower blood ammonia levels.

The main treatment options for urea cycle disorders include amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, and others. Amino acid supplements provide one or more of the nine essential amino acids that the body cannot produce naturally. Treatments address various enzyme deficiencies, including OTC (ornithine transcarbamylase), AS (argininosuccinate synthetase, citrullinemia), AG (arginase), AL (argininosuccinate lyase), and CPS1 (carbamoyl phosphate synthase). These therapies are administered orally or by injection and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The urea cycle disorders treatment market includes revenues earned by entities by hemodialysis, dietary management, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The urea cycle disorders treatment market also includes sales of arginine, sodium phenylacetate, sodium benzoate, and carglumic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.